Smoking and Psychosis: Insights from the PATH Study
Psychopharmacology and Psychiatry Updates
Release Date: 04/21/2024
Informed Consent and SSRIs: Discussing the Risk of Irreversible Sexual Side Effects
Psychopharmacology and Psychiatry Updates
In this episode, we delve into the potential for irreversible sexual dysfunction after SSRI use, based on a large-scale Israeli study. Could a few months or even days of antidepressant treatment lead to permanent erectile issues? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.
info_outline
Mastering Clozapine: Adverse Effect Management
Psychopharmacology and Psychiatry Updates
In this episode, we discuss the management of common adverse effects associated with clozapine treatment, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. How can clinicians mitigate these risks while optimizing treatment outcomes for patients with treatment-resistant schizophrenia? Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
info_outline
Preventing Depression and Anxiety Relapse in Youth
Psychopharmacology and Psychiatry Updates
In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
info_outline
Charting the Clozapine Course: Titration and Monitoring
Psychopharmacology and Psychiatry Updates
In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
info_outline
Smoking and Psychosis: Insights from the PATH Study
Psychopharmacology and Psychiatry Updates
In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
info_outline
Clozapine: The Gold Standard for Treatment-Resistant Schizophrenia
Psychopharmacology and Psychiatry Updates
In this episode, we delve into the use of clozapine for treatment-resistant psychosis and mood disorders. When should clinicians consider clozapine, and what do expert guidelines recommend? Dr. Brian Miller guides us through the evidence and best practices for utilizing this powerful but often underused medication. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.
info_outline
Balancing Benefits and Risks: Lithium in Child and Adolescent Psychiatry
Psychopharmacology and Psychiatry Updates
In this episode, we explore the role of lithium in treating pediatric bipolar disorder and conduct disorder. Is lithium a viable option for managing these complex conditions in children and adolescents, or are other medications more effective? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.
info_outline
Orchestrating Nutrition and Medication: Micronutrient Therapy in Practice
Psychopharmacology and Psychiatry Updates
In this episode, we explore real-world clinical cases demonstrating how broad-spectrum micronutrients can complement existing interventions for ADHD, emotional dysregulation, and mood instability. Can close monitoring and expert guidance optimize the integration of nutritional supplementation with pharmacologic treatments to create a harmonious, personalized approach? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
info_outline
Zuranolone: A New Dawn for Postpartum Depression Treatment
Psychopharmacology and Psychiatry Updates
In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D.
info_outline
Micronutrients for Psychiatric Disorders: Optimizing Clinical Use
Psychopharmacology and Psychiatry Updates
In this episode, we explore practical clinical tips for using broad-spectrum micronutrient supplements to treat mental health conditions. Can an individual's nutritional needs surpass population standards? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D.
info_outlineIn this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.